Denali Therapeutics
This role partners with experts across Discovery and Development to build biomarker strategies that enable biomarker-driven clinical development plans supporting dose selection, biomarker proof-of-concept, and deep patient phenotyping in rare, genetically defined, and/or neurodegenerative diseases. It brings broad drug development and regulatory expertise together with biomarker strategy leadership to advance large-molecule therapeutics through the clinical pipeline and approval. The position involves leading complex cross-functional biomarker research projects, defining strategies to generate clinical evidence, and contributing to regulatory submissions for accelerated approval.
Headquarters
South San Francisco, California, United States
Company Size
201-500 employees
Founded
2015
Denali Therapeutics brings the power of biotherapeutics to the whole body, including the brain. We discover, develop and deliver medicines for people living with serious diseases.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Denali Therapeutics.
23% above the average for this role
Precision Medicine Global Biomarker Lead, Rare Disease
lifelancer
Associate Director, Biomarker Analysis
Crinetics Pharmaceuticals
Precision Medicine Global Biomarker Lead , Rare Disease
Amgen
Director - Mass Spectrometry-based Biomarker Discovery - Neuroscience
Eli Lilly and Company
Clinical Biomarker Lead, Senior Scientist
Ipsen
Associate Director, Clinical Biomarker
lifelancer